Develops first-in-class fascin inhibitor drugs to prevent and treat cancer metastasis and to boost anti-tumor immune responses for patients with metastatic cancer. Targets tumor-cell motility and antigen-presenting cells to inhibit metastasis and synergize with immune checkpoint inhibitors.